Compare GE Aerospace (GE) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs McKesson Corporation — how do they compare? GE Aerospace trades at $348.77 (market cap $375.97B), while McKesson Corporation trades at $822.17 (market cap $93.23B). The key difference: GE Aerospace is far larger — about 4× McKesson Corporation's market cap, and GE Aerospace pays the higher dividend (0.52%). Which is the better fit depends on your goals.
| GE | MCK | |
|---|---|---|
Market Cap | $375.97B | $93.23B |
Sector | Industrials | Health |
52-Week High | $378.68 | $995.69 |
52-Week Low | $259.00 | $659.01 |
Enterprise Value | $385.26B | $97.87B |
Dividend Yield | 0.52% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE trades at $353.73, up 0.09% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q1 2026 EPS of $1.86 versus $1.60 expected, driven by robust aerospace demand and defense contract wins. Revenue grew to $45.86 billion in 2025, with net income margin improving to 18.98%. Analysts maintain a strong buy consensus with a $402.63 price target, reflecting optimism about order growth and backlog strength.
Outlook remains positive given earnings momentum and strategic investments in MRO and propulsion, though high valuation ratios (P/E 43.94) and debt levels pose risks. The stock offers upside to consensus targets but faces pressure from rising costs and competitive dynamics in aerospace and defense sectors.
McKesson (MCK) trades at $803.37, down 1.1% on the day, with technical indicators showing a neutral to bullish bias as the price sits near pivot point $805. The company demonstrates strong fundamental momentum with revenue growing from $264B in 2022 to $359.1B in 2025, and a consistent track record of beating earnings estimates in recent quarters. Analyst sentiment is overwhelmingly positive, with 80% recommending Buy and a consensus price target of $932.83, representing a 16% upside from current levels.
The outlook for MCK is favorable, supported by robust revenue growth, expanding profitability, and strong analyst conviction. Key opportunities include continued execution in specialty pharma and oncology services. Primary risks involve policy changes affecting healthcare distribution, intense industry competition, and execution challenges in integrating growth initiatives, which could pressure margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
